Stock listing

Munich:NNFN MannKind Corporation Aktie

German listing (Munich) of MannKind Corporation · home listing NASDAQ:MNKD

Follow MannKind Corporation into a list and get an email when it puts out news.

Home listing price · NASDAQ:MNKD

$3.04 USD -0.15 (-4.7%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:MNKD

MannKind Corporation logo
Ticker
Munich:NNFN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • Mannkind (NASDAQ:MNKD) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Mannkind (NASDAQ:MNKD) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Mannkind (NASDAQ:MNKD) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 9:00 AM ET

    Watch Transcript

Latest news

MannKind to Participate in the Chardan Healthcare Conference

Oct 14, 2026

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Oct 9, 2026

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Sep 9, 2026

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 5, 2026

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Jul 29, 2026

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

Jul 28, 2026

MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

Jul 27, 2026

MannKind Announces $50 Million Private Placement

Jul 24, 2026

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Jun 23, 2026

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Jun 5, 2026

All MannKind Corporation news

Financings

  • Private placement of unstated

    Aug 5, 2026

    Closed: US$50M raised · US$3.89 a share

    Buyers: Frazier Life Sciences

    Use of proceeds: To fund the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow

    Announced Jul 24, 2026 · Closed Aug 5, 2026

Read by 6ix AI from the company's releases

Decks

MannKind Corporation on 6ix

Sector
Health care
Industry
Biotechnology
News releases
34 in the last 12 months · 206 in all · newest Oct 14, 2026 · oldest 2019
Calls
20 calls with a replay · 20 with a transcript · latest Aug 5, 2026
Decks
4 decks · latest August 2026

Where MannKind Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:MNKD · Home listingNASDAQUnited StatesUSD
BOATS:MNKDBOATSUnited StatesUSD
gettex:NNFNgettexGermanyEUR
LS Exchange:A2DMZLLS ExchangeGermanyEUR
Lang & Schwarz:A2DMZLLang & SchwarzGermanyEUR
Tradegate:NNFNTradegateGermanyEUR
Munich:NNFN · This pageMunichGermanyEUR
BX Swiss:NNFNBX SwissSwitzerlandCHF
Dusseldorf:NNFNDusseldorfGermanyEUR
Frankfurt:NNFNFrankfurtGermanyEUR
Stuttgart:NNFNStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about MannKind Corporation.